Consequently, we suggest a considerable number of unknown EM AML patients currently still classified as “normal” AML without clinical apparent extramedullary manifestations at diagnosis for which LOX could also be a potential marker for prognosis. This evidence concerns the gene LOX and acute myeloid leukemia.